ARTV vs MBIO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ARTV Captures Institutional Edge (2โ1 Pillars ยท 3โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Artiva Biotherapeutics, Inc. Common Stock (ARTV) driven by superior Momentum & Technical, Options & Structure while MBIO counters with relative strength in Growth & Margin. Fundamentally, ARTV trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus MBIO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ARTV sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro) against MBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ARTV | MBIO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $198.2M | $3.2M | Larger Scale | ARTV |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -100.0% | +0.0% | Higher Growth | MBIO |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -43.6% | -43.1% | Higher ROE | MBIO |
| 52-Week Range Position Momentum | 8% ($3โ$15) | 3% ($0โ$1) | Stronger Trend | ARTV |
| Beta / 30D Volatility Risk Regime | 1.73ฮฒ ยท 114% Vol | 0.69ฮฒ ยท 85% Vol | Lower Realized Risk | MBIO |
| Unified Institutional Score Composite Signal | 48.5 / 100 (HOLD) | 42.9 / 100 (HOLD) | Higher Composite | ARTV |